Physician profile
Jeffrey D Small
NPI 1750375549
$6,348.90
in general payments reported to CMS, 2019-2025
33 companies · $868 in 2025
The $868 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $372 · 2021: $1,066 · 2022: $1,150 · 2023: $1,049 · 2024: $1,038 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,776 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,775.96 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,734.13 | 2019-2025 | Myrbetriq, Veozah, Xtandi |
| Sumitomo Pharma America, INC. | $912.66 | 2023-2025 | Orgovyx, Gemtesa |
| Myovant Sciences INC. | $741.33 | 2021-2022 | |
| Pfizer INC. | $597.46 | 2019-2025 | |
| Coloplast Corp | $418.33 | 2020-2023 | Porges Coloplast, Speedicath |
| Abbvie INC. | $192.44 | 2019-2025 | Botox, Lupron Depot |
| Allergan, INC. | $170.31 | 2019-2021 | |
| Olympus America INC. | $147.62 | 2025 | Itind System |
| Boston Scientific Corporation | $121.08 | 2020-2024 | Greenlight Xps |
| Tolmar Pharmaceuticals, INC. | $116.93 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $114.37 | 2020-2022 | |
| 180 Medical, INC. | $107.32 | 2021-2024 | |
| Urogen Pharma, INC. | $103.99 | 2021-2025 | |
| Photocure INC | $100.15 | 2019-2020 | |
| Progenics Pharmaceuticals, INC. | $86.09 | 2023-2024 | Pylarify |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $78.95 | 2019-2025 | Adstiladrin |
| Novartis Pharmaceuticals Corporation | $78.33 | 2023-2025 | |
| Accord Healthcare, INC. | $75.81 | 2022 | |
| Neotract INC. | $65.55 | 2019-2020 | |
| Janssen Biotech, INC. | $49.70 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $49.02 | 2022 | |
| Tolmar, INC. | $48.83 | 2023-2024 | |
| Immunitybio, INC. | $35.02 | 2025 | |
| Acelrx Pharmaceuticals, INC. | $33.90 | 2019-2022 | |
| Laborie Medical Technologies Corp. | $26.24 | 2021 | |
| Urovant Sciences INC | $23.60 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.85 | 2023 | Entyvio |
| Endo Pharmaceuticals INC. | $20.02 | 2019 | |
| Dentsply Ih INC. | $18.56 | 2021 | |
| Teleflex LLC | $17.28 | 2023 | Urolift |
| Vertex Pharmaceuticals Incorporated | $14.66 | 2024 | |
| Metuchen Pharmaceuticals | $14.17 | 2019 | |
| Hollister Incorporated | $13.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Small listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.